Tag: Lexicon Pharmaceuticals

novartis-oncology-logo

Carcinoid Cancer Foundation Thanks Symposium Sponsors

April 21, 2011

There’s still time to register for the Carcinoid Cancer Foundation’s 14th annual  symposium for patients, family, friends, and healthcare professionals, which will be held on Sunday, May 1st at Mount Sinai Medical Center in New York City.  The Foundation…

READ MORE
Arthur T. Sands, MD, PhD, President and Chief Executive Officer, Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc. Clinical Trial Recruiting Carcinoid Syndrome Patients

September 10, 2010

Patients with carcinoid syndrome, whose symptoms are not managed by octreotide therapy, are being recruited for a Phase 2 clinical trial of Lexicon Pharmaceuticals’ LX1606 (a.k.a. LX1032).  The trial has been given Fast Track status in the U.S. and …

READ MORE

Carcinoid Syndrome Clinical Trial to Be Featured on Webcast

April 6, 2010

Lexicon Pharmaceuticals’ clinical trial LX1032 for carcinoid syndrome will be among the clinical programs that are reviewed in-depth on April 8, 2010 when the company holds its Annual R&D Day from 7:30 to 11:00 am, Eastern Time, in New York City. …

READ MORE